Rein Therapeutics (NASDAQ:RNTX) Now Covered by Analysts at Maxim Group

Maxim Group initiated coverage on shares of Rein Therapeutics (NASDAQ:RNTX) in a research report sent to investors on Monday,Benzinga reports. The firm issued a buy rating and a $4.00 price target on the stock.

Other analysts have also issued research reports about the company. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. HC Wainwright reduced their price objective on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.00.

Rein Therapeutics Price Performance

Shares of NASDAQ:RNTX opened at $0.84 on Monday. Rein Therapeutics has a 1 year low of $0.83 and a 1 year high of $2.18. The company has a market cap of $72.20 million, a PE ratio of -0.44 and a beta of 1.35. The stock’s 50-day moving average is $0.99 and its 200 day moving average is $1.20.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30. Analysts expect that Rein Therapeutics will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Rein Therapeutics

Several hedge funds have recently made changes to their positions in the company. Voss Capital LP grew its stake in Rein Therapeutics by 59.2% in the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after purchasing an additional 1,577,437 shares during the period. Vanguard Group Inc. lifted its position in Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after buying an additional 284,300 shares during the period. Cable Car Capital LP bought a new stake in shares of Rein Therapeutics during the 2nd quarter valued at $588,000. Sigma Planning Corp boosted its holdings in shares of Rein Therapeutics by 41.0% during the 1st quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after buying an additional 101,400 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Rein Therapeutics by 15.1% in the 4th quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after buying an additional 37,244 shares during the period. 90.89% of the stock is currently owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.